Gholam A. Peyman, M.D., Joins InSite Vision's Scientific Advisory Board


Gholam A. Peyman, M.D., Joins InSite Vision's Scientific Advisory Board

Dr. Peyman is a Recipient of the National Medal of Technology and Innovation and the Inventor of Lasik Eye Surgery

ALAMEDA, Calif.--(BUSINESS WIRE)-- InSite Vision Incorporated (OTCBB: INSV) today announced that Dr. Gholam A. Peyman has joined its Scientific Advisory Board (SAB) which helps to guide and shape the InSite Vision research programs in the development of novel ophthalmic medicines. Members of the SAB are leaders in ophthalmic research, treatment and clinical drug development and include Richard Lindstrom, M.D., Gary Foulks, M.D., Michael Lemp, M.D., and Kelly Nichols, O.D., M.P.H., Ph.D. Kamran Hosseini, M.D., Ph.D., InSite's Chief Medical Officer, is the leader of the SAB and Brian Levy, O.D., a member of InSite's Board of Directors participates in all SAB meetings.

"We are elated that Dr. Peyman has joined the InSite Vision Scientific Advisory Board and I look forward to his counsel as we advance our broad product development pipeline," said Dr. Hosseini. "Our ability to attract world-class innovators to our SAB reflects the significant progress we are achieving in the development of ocular medicines."

Dr. Peyman is currently a professor of Basic Medical Sciences at the University of Arizona, emeritus professor of Tulane University and a pioneer in vitreoretinal surgery, intraocular drug delivery, refractive surgery and the chorioretinal biopsy and intraocular tumors technique. He is the recipient of the nation's highest honor for technology achievement, The National Medal of Technology and Innovation, awarded by the President of the United States to America's leading innovators. He is an active retina surgeon who also is a prolific and successful inventor with 136 issued patents in a wide variety of devices, intraocular drug delivery, surgical techniques as well as new methods of diagnosis and treatment.

Dr. Peyman is most widely known as the inventor of Lasik eye surgery, a vision correction procedure that allows people to see clearly without glasses. His first Lasik U.S. patent was issued in 1989. In 2005, he was selected by more than thirty thousand ophthalmologists to become one of the thirteen living ophthalmologists inducted into the Hall of Fame of Ophthalmology.

Some of his past innovations include: evaluating the injection of antibiotics into the vitreous for the treatment of endophthalmitis (1971); development of eye-wall resection (1970) and endoresection of intraocular tumors (1985); performance of the first retinochoroidal biopsy (1975), endolaser (1980) and transplantation of retinal pigment epithelial cells (1989) for patients with age-related macular degeneration. Additionally, he and an associate developed the first telescoptic intraocular lens (1987 and 2006) for patients with macular diseases and described the first pressure-controlled valve for glaucoma surgery.

Dr. Peyman has authored or co-authored over 900 scientific journal articles. He is the recipient of numerous awards including the first Pfizer/ARVO translational award and the Life Achievement Award of the American Academy of Ophthalmology.

About InSite Vision

InSite Vision is advancing new ophthalmologic products for unmet eye care needs based on its innovative DuraSite® platform technologies. The DuraSite and DuraSite 2® drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs.

The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb. InSite Vision is also advancing three novel ophthalmic therapeutics through Phase 3 clinical studies: AzaSite Plus and DexaSite for the treatment of blepharitis, and BromSite for pain and inflammation associated with ocular surgery. For further information on InSite Vision, please visit

AzaSite®, DuraSite® and DuraSite 2® are registered trademarks of InSite Vision Incorporated. AzaSite Plus, BromSite and DexaSite are trademarks of InSite Vision Incorporated.
BESIVANCE® and Bromday™ are registered trademarks of Bausch + Lomb Incorporated.

InSite Vision
Louis Drapeau, 510-747-1220
Chief Financial Officer
Media and Investor inquiries
BCC Partners
Michelle Corral, 415-794-8662
Karen L. Bergman, 650-575-1509

KEYWORDS: United States North America California


The article Gholam A. Peyman, M.D., Joins InSite Vision's Scientific Advisory Board originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.